首都医科大学附属北京地坛医院,北京市朝阳区京顺东街8号,100015
jyuy11@126.com
收稿:2022-05-12,
修回:2022-09-23,
纸质出版:2023-03-02
移动端阅览
姜婷婷,杨志云,王宪波等.基于Stroop测试探讨益气养阴解毒化瘀方加减联合西药治疗轻微型肝性脑病的临床疗效[J].中医杂志,2023,64(05):490-497.
JIANG Tingting,YANG Zhiyun,WANG Xianbo,et al.Clinical Efficacy of Yiqi Yangyin Jiedu Huayu Formula (益气养阴解毒化瘀方) Modifications Combined with Western Medicine in the Treatment of Minimal Hepatic Encephalopathy based on the Stroop Test[J].Journal of Traditional Chinese Medicine,2023,64(05):490-497.
姜婷婷,杨志云,王宪波等.基于Stroop测试探讨益气养阴解毒化瘀方加减联合西药治疗轻微型肝性脑病的临床疗效[J].中医杂志,2023,64(05):490-497. DOI: 10.13288/j.11-2166/r.2023.05.011.
JIANG Tingting,YANG Zhiyun,WANG Xianbo,et al.Clinical Efficacy of Yiqi Yangyin Jiedu Huayu Formula (益气养阴解毒化瘀方) Modifications Combined with Western Medicine in the Treatment of Minimal Hepatic Encephalopathy based on the Stroop Test[J].Journal of Traditional Chinese Medicine,2023,64(05):490-497. DOI: 10.13288/j.11-2166/r.2023.05.011.
目的
2
评价益气养阴解毒化瘀方加减联合西药治疗轻微型肝性脑病的临床疗效及安全性。
方法
2
纳入经Stroop测试诊断为轻微型肝性脑病患者100例,采用随机对照试验方法,以1∶1比例分为益气养阴解毒化瘀方加减联合西医治疗组(中西医结合治疗组)和西医治疗组进行治疗,记录两种疗法对轻微型肝性脑病患者治疗前及治疗4周后的Stroop测试时间(包括总关闭阶段时间、正确完成关闭阶段的次数、总开放阶段时间、正确完成开放阶段的次数、总开放阶段时间+总关闭阶段时间)和中医证候积分,并评价疗效;分别于治疗前及治疗1、2、4周后记录患者终末期肝病模型(MELD)评分,并检测肝功能[包括血氨(BA)、丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、白蛋白(ALB)、血清总胆红素(TBiL)]、凝血功能[包括凝血酶原活动度(PTA)、国际标准化比值(INR)]及粒淋比(NLR),并观察患者生命体征,检测血常规及电解质肾功能,记录不良事件。
结果
2
治疗后,中西医结合治疗组Stroop测试结果的总关闭阶段时间[97.01(85.61,110.98)s]、总开放阶段时间[106.47(93.82,125.89)s]、总开放阶段时间+总关闭阶段时间[201.63(180.72,231.34)s]较本组治疗前缩短,且分别较西医治疗组的109.53(97.56,140.37)s、127.46(106.66,148.02)s、234.40(212.19,283.68)s缩短更明显(
P
<0.05或
P
<0.01)。中西医结合治疗组有效率94%,优于西医治疗组的72%(
P
<0.01)。中西医结合治疗组治疗1、2、4周后ALT、AST、TBiL、BA、INR、NLR、MELD评分及中医证候积分逐渐下降,ALB、PTA上升,且除ALT外,其余指标改善均优于西医治疗组(
P
<0.05或
P
<0.01)。中西医结合治疗组1例患者在治疗2周后出现腹泻,调整方药后好转。
结论
2
益气养阴解毒化瘀方加减联合西药治疗轻微型肝性脑病能改善患者认知能力,提高治疗有效率,且安全性好。
Objective
2
To evaluate the efficacy and safety of
Yiqi Yangyin Jiedu Huayu Formula
(益气养阴解毒化瘀方) modifications combined with western medicine in the treatment of minimal hepatic encephalopathy (MHE).
Methods
2
In a randomized controlled study, 100 patients diagnosed as MHE by the Stroop test were divided into the integrated treatment group (
Yiqi Yangyin Jiedu Huayu Formula
modifications combined with western medicine) and western medicine group at a ratio of 1∶1. Before and after 4-week treatment, the Stroop test indicators including total OFF stage time, the number of correct completion of the OFF stage, total ON stage time, the number of correct completion of the ON stage, and total ON and OFF stage time, and TCM syndrome scores were assessed to evaluate the effects. Before and after 1-, 2-, and 4-week treatment, score of the model for end-stage liver disease (MELD), liver function indicators including blood ammonia (BA), alanine aminotransferase (ALT), aspartic acid aminotransferase (AST), albumin (ALB), and serum total bilirubin (TBiL), coagulation function indicators including prothrombin activity (PTA) and international normalized ratio (INR), and granulocyte-to-lymph ratio (NLR) were assessed, and the patient's vital signs, blood routine and electrolyte renal function were assessed, the adverse events were also recorded.
Results
2
After treatment, the total OFF stage time [97.01 (85.61,110.98)s], total ON stage time [106.47 (93.82, 125.89)s], total ON and OFF stage time [201.63 (180.72, 231.34)s] of Stroop test in the integrated treatment group significantly decreased, and were shorter than those in the western medicine group [respectively 109.53, (97.56, 140.37)s, 127.46 (106.66, 148.02)s, and 234.40 (212.19, 283.68)s] (
P
<0.05 or
P
<0.01). The effective rate of the integrated treatment group was 94%, higher than 72% of the western medicine group (
P
<0.01). The levels of ALT, AST, TBiL, BA, INR, NLR, the MELD score, and the TCM syndrome score in the integrated treatment group gradually decreased after 1-, 2- and 4-week treatment, while the levels of ALB and PTA increased, and more changes were seen than the western medicine group except for the ALT level (
P
<0.05 or
P
<0.01). Diarrhea occurred in one patient in the integrated treatment group after 2-week treatment, but was improved after adjusting the prescription.
Conclusion
2
The combination of
Yiqi Yangyin Jiedu Huayu Formula
modifications and western medicine in the treatment of MHE can obviously improve the cognitive ability, increase the effective rate and is safe.
BARONE M , SHAHINI E , IANNONE A , et al . Critical flicker frequency test predicts overt hepatic encephalopathy and survival in patients with liver cirrhosis [J]. Dig Liver Dis , 2018 , 50 ( 5 ): 496 - 500 .
FICHET J , MERCIER E , GENEE O , et al . Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy [J]. J Crit Care , 2009 , 24 ( 3 ): 364 - 370 .
LABENZ C , ADARKWAH CC , WÖRNS MA , et al . Ma-nagement of hepatic encephalopathy in Germany: a survey among physicians [J]. Z Gastroenterol 2020 , 58 ( 1 ): 49 - 56 .
STROOP JR . Studies of interference on serial verbal reactions [J]. J Exp Psychol Gen , 1935 , 18 ( 6 ): 643 - 662 .
BAJAJ JS , THACKER LR , HEUMAN DM , et al . The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy [J]. Hepatology , 2013 , 58 ( 3 ): 1122 - 1132 .
中华医学会肝病学分会 . 肝硬化肝性脑病诊疗指南 [J]. 临床肝胆病杂志 , 2018 , 34 ( 10 ): 2076 - 2089 .
VILSTRUP H , AMODIO P , BAJAJ J , et al . Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver [J]. Hepatology , 2014 , 60 ( 2 ): 715 - 735 .
姚春 , 姚凡 , 谢武 , 等 . 大黄煎剂保留灌肠治疗轻微肝性脑病临床研究 [J]. 辽宁中医杂志 , 2013 , 40 ( 3 ): 474 - 476 .
章亮 . 清肠合剂保留灌肠治疗肝硬化轻微型肝性脑病的临床研究 [J]. 中国中医药科技 , 2015 , 22 ( 1 ): 12 - 14 .
王阳刚 , 王秀峰 , 王娜 , 等 . 六味醒神颗粒治疗轻微型肝性脑病临床研究 [J]. 河南中医 , 2016 , 36 ( 12 ): 2112 - 2114 .
姜婷婷 , 江宇泳 , 王融冰 , 等 . 轻微型肝性脑病的发病特征及中医证素规律初探 [J]. 中医药学报 , 2019 , 47 ( 1 ): 68 - 72 .
姜婷婷 , 王融冰 , 杨志云 , 等 . 轻微型肝性脑病的发病危险因素及中医证型分布规律 [J]. 北京中医药 , 2019 , 38 ( 3 ): 211 - 213 .
中华医学会肝病学分会 . 肝硬化诊治指南 [J]. 中华肝脏病杂志 , 2019 , 27 ( 11 ): 846 - 865 .
王黎 , 朱璇 , 李洁 , 等 . 手机版斯特鲁谱测试在筛查轻微型肝性脑病中的应用价值 [J]. 中华神经医学杂志 , 2017 , 7 ( 16 ): 711 - 714 .
ZENG X , LI XX , SHI PM , et al . Utility of the encephal App Stroop test for covert hepatic encephalopathy screening in Chinese cirrhotic patients [J]. J Gastroenterol Hepatol , 2019 ( 34 ): 1843 - 1850 .
刘琼 , 蔡克银 . 大黄煎剂保留灌肠治疗肝性脑病的临床观察 [J]. 世界最新医学信息文摘 , 2017 , 17 ( 95 ): 130 - 131 .
李立明 , 詹思延 , 谭红专 , 等 . 临床流行病学 [M]. 北京 : 人民卫生出版社 , 2011 : 139 - 140 .
郑筱萸 . 中药新药临床研究指导原则(试行) [M]. 北京 : 中国医药科技出版社 , 2002 : 附录 .
KAMATH PS , WIESNER RH , MALINCHOC M , et al . A model to predict survival in patients with end-stage liver disease [J]. Hepatology , 2001 , 33 ( 2 ): 464 - 470 .
XU XY , DING HG , LI WG , et al . Chinese guidelines on management of hepatic encephalopathy in cirrhosis [J]. World J Gastroenterol , 2019 , 25 ( 36 ): 5403 - 5422 .
PUGH RN , MURRAY-LYON IM , DAWSON JL , et al . Transection of the oesophagus for bleeding oesophageal varices [J]. Br J Surg , 1973 , 60 ( 8 ): 646 - 649 .
JIANG TT , LIU XL , JIANG YY , et al . Minimalhepatic encephalopathy and Biejia-Ruangan are associated with first hospital readmission in nonalcoholic cirrhosis patients [J]. Evid Based Complement Alternat Med , 2021 , 2021 : 6652858 . doi: 10.1155/2021/6652858 http://dx.doi.org/10.1155/2021/6652858 .
ROMAN E , CORDOBA J , TORRENS M , et al . Minimal hepatic encephalopathy is associated with falls [J]. Am J Gastroenterol , 2011 , 106 ( 3 ): 476 - 482 .
RIDOLA L , NARDELLI S , GIOIA S , et al . Quality of life in patients with minimal hepatic encephalopathy [J]. World J Gastroenterol , 2018 , 24 ( 48 ): 5446 - 5453 .
秦军胜 , 王洪亮 . 轻微型老年肝性脑病患者血氨、脑血流动力学指标变化情况及对认知功能的影响 [J]. 检验医学与临床 , 2022 , 19 ( 6 ): 730 - 733 .
ALDRIDGE DR , TRANAH EJ , SHAWCROSS DL . Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation .[J]. J Clin Exp Hepatol , 2015 , 5 ( Suppl 1 ): 7 - 20 .
RICE J , DODGE JL , BAMBHA KM , et al . Neutrophil-to-Lymphocyte ratio associates independently with morta-lity in hospitalized patients with cirrhosis [J]. Clin Gastroenterol Hepatol , 2018 , 16 ( 11 ): 1786 - 1791 .
王宪波 , 高方媛 , 刘尧 . 中性粒细胞与淋巴细胞比值:一项评价肝细胞癌患者预后的新指标 [J]. 临床肝胆病杂志 , 2016 , 32 ( 4 ): 649 - 652 .
梁利民 , 徐鹤翔 , 郑吉顺 , 等 . 中性粒细胞与淋巴细胞比值对失代偿期肝硬化患者预后的评估价值 [J]. 临床肝胆病杂志 , 2019 , 35 ( 4 ): 790 - 795 .
D'AMICO G , GARCIA-TSAO G , PAGLIARO L . Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies [J]. J Hepatol , 2006 , 44 ( 1 ): 217 - 231 .
VOLK ML , TOCCO RS , BAZICK J , et al . Hospital readmissions among patients with decompensated cirrhosis [J]. Am J Gastroenterol , 2012 , 107 ( 2 ): 247 - 252 .
BAJAJ JS , HEUMAN DM , STERLING RK , et al . Validation of EncephalApp, smartphone-based Stroop test, for the diagnosis of covert hepatic encephalopathy [J]. Clin Gastroenterol Hepatol , 2015 , 13 ( 10 ): 1828 - 1835 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号